



ASX release

26 May 2010

Positive Medicare coverage ruling in Michigan

- Requires Medicare plan to cover SphygmoCor System

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor[®] system, which measures central blood pressures and arterial stiffness non-invasively, today announced a positive case ruling by an Administrative Law Judge for the Centers for Medicare and Medicaid. Specifically, the judge found that a Medicare health plan in the state of Michigan must provide coverage for use of the SphygmoCor System.

Medicare, the US Government health plan for people over age 65 and those having certain disabilities, covers over 45 million Americans. Medicare is administered primarily by private contractors on a state or regional basis. The Michigan Medicare carrier is one of the largest Medicare contractors, covering over 5 million lives across four states. "This is a significant step forward in the clinical adoption of SphygmoCor in the US market," said Duncan Ross, AtCor Medical President and CEO. "After careful review of the record and facts of the case, the judge ruled that the health plan must provide coverage for the SphygmoCor system."

A physician used SphygmoCor to treat a high-risk patient with an extensive history of hypertension whose blood pressure was previously uncontrolled using standard brachial cuff blood pressure for drug therapy selection and guidance. Use of AtCor Medical's SphygmoCor technology enabled the physician to control her blood pressure, improve her cardiac function and reduce target organ damage.

A number of private health plans have reimbursed physicians for SphygmoCor assessments using an unlisted cardiovascular services code. AtCor Medical continues to drive clinical adoption through local reimbursement decisions and the company remains on track to file for a CPT (Common Procedural Terminology) code specific to central blood pressure assessment as early as November 2010.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au